<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01230749</url>
  </required_header>
  <id_info>
    <org_study_id>CR017401</org_study_id>
    <secondary_id>41443532EDI2001</secondary_id>
    <nct_id>NCT01230749</nct_id>
  </id_info>
  <brief_title>A Study of Multiple Oral Doses of JNJ-41443532 in Patients With Type 2 Diabetes Mellitus</brief_title>
  <official_title>A Double-Blind, Randomized, Placebo- and Active Comparator-Controlled, 4-Week Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Oral Doses of JNJ-41443532 in Subjects With Type 2 Diabetes Mellitus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johnson &amp; Johnson Pharmaceutical Research &amp; Development, L.L.C.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Johnson &amp; Johnson Pharmaceutical Research &amp; Development, L.L.C.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (what the
      body does to the medication) and pharmacodynamics (what the medication does to the body) of
      treatment with JNJ-41443532 relative to treatment with placebo in type 2 diabetes mellitus
      participants.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized (the study medication is assigned by chance), double-blind (neither
      investigator nor participant knows the treatment that the participant receives), multicenter
      (study conducted at multiple sites), and placebo (an inactive substance that is compared with
      a medication to test whether the medication has a real effect in a clinical study) and active
      comparator (an established effective treatment that is compared with a medication to test
      whether the medication has a real effect in a clinical study) controlled study (placebo or
      active comparator is compared with the study medication to test whether the study medication
      has a real effect in clinical study). The study consists of 4 phases: screening phase (45
      days before administration of study medication); pre-dosing run-in phase (a phase before a
      clinical study is commenced when no treatment is given. In this study, participant's glucose
      level will be observed during run-in-phase: days 15 to 1 before administration of study
      medication); treatment phase, and follow-up phase (7 to 10 days after the last dose of the
      study medication). Approximately 88 participants will be enrolled in this study. All
      participants will be randomly assigned to 4 treatment arms: JNJ-41443532 250 mg; JNJ-41443532
      1000 mg; pioglitazone arm; and placebo. Safety evaluations will include assessment of adverse
      events including ocular assessments, clinical laboratory tests, electrocardiogram, vital
      signs, and physical examination which will be monitored throughout the study. The maximum
      study duration for each participant will be approximately 12 weeks.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2010</start_date>
  <completion_date type="Actual">June 2011</completion_date>
  <primary_completion_date type="Actual">June 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline (Day -1) to Day 28 in Twenty-Four-Hour Weighted Average Glucose (24-Hour WAG)</measure>
    <time_frame>From baseline (Day -1) to Day 28</time_frame>
    <description>Difference is calculated as the change in 24-hour WAG in Least Square Mean (LSM) from baseline to Day 28 of each treatment group (pioglitazone, JNJ-41443532 250 mg, JNJ-41443532 1000 mg, and placebo). The statistical analyses shows the treatment differences (ie, each study medication group minus placebo) in the LSM change. 24-hour WAG is defined as the area under the plasma glucose concentration time curve over 0 to 24 hours, divided by 24.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Day 28 in Fasting Plasma Glucose (FPG)</measure>
    <time_frame>From baseline to Day 28</time_frame>
    <description>Difference is calculated as the change in FPG in Least Square Mean (LSM) from baseline to Day 28 of each treatment group (pioglitazone, JNJ-41443532 250 mg, JNJ-41443532 1000 mg, and placebo). The statistical analyses shows the treatment differences (ie, each study medication group minus placebo) in the LSM change.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Day 28 in Insulin Secretion</measure>
    <time_frame>From baseline to Day 28</time_frame>
    <description>Difference is calculated as the change in insulin secretion in Least Square Mean (LSM) from baseline to Day 28 of each treatment group (pioglitazone, JNJ-41443532 250 mg, JNJ-41443532 1000 mg, and placebo). The statistical analyses shows the treatment differences (ie, each study medication group minus placebo) in the LSM change. Insulin secretion is measured by the absolute change in Homeostasis Model Assessment of steady state islet beta cell (HOMA-%B). HOMA-%B calculated as: (360 multiplied by Insulin [pmol/L]) divided by ([Glucose {mg/dL} minus 63] multiplied by 6.945). Higher value is better (signifies improvement relative to baseline).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Day 28 in Insulin Resistance</measure>
    <time_frame>From baseline to Day 28</time_frame>
    <description>Difference is calculated as the change in insulin resistance in Least Square Mean (LSM) from baseline to Day 28 of each treatment group (pioglitazone, JNJ-41443532 250 mg, JNJ-41443532 1000 mg, and placebo). The statistical analyses shows the treatment differences (ie, each study medication group minus placebo) in the LSM change. Insuline sensitivity is measured by absolute change in Homeostasis Model Assessment of insulin resistance (HOMA-IR). Insulin sensitivity is HOMA-%S and HOMA-IR is the reciprocal of HOMA-%S. HOMA-IR calculated as: (Glucose [mg/dL]) multiplied by Insulin [pmol/L]) divided by (405 multiplied by 6.945). Lower value is better (signifies improvement relative to baseline).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Day 28 in Systemic Levels of Interleukin 6 (IL-6)</measure>
    <time_frame>From baseline to Day 28</time_frame>
    <description>Difference is calculated as the geometric mean change in IL-6 from baseline to Day 28 of each treatment group (JNJ-41443532 250 mg, JNJ-41443532 1000 mg, and placebo). The statistical analyses shows the treatment differences (ie, each study medication group minus placebo) in the geometric mean change. IL-6 is a systemic inflammatory markers and is an independent predictors of insulin resistance and progression to type 2 diabetes mellitus. IL-6 was not measured for pioglitazone guoup. The unit of IL-6 is picograms per milliliter (pg/mL).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Day 28 in Systemic Levels of Interleukin 18 (IL-18)</measure>
    <time_frame>From baseline to Day 28</time_frame>
    <description>Difference is calculated as the geometric mean change in IL-18 from baseline to Day 28 of each treatment group (JNJ-41443532 250 mg, JNJ-41443532 1000 mg, and placebo). The statistical analyses shows the treatment differences (ie, each study medication group minus placebo) in the geometric mean change. IL-18 was not measured for pioglitazone group. The unit of IL-18 is picograms per milliliter (pg/mL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Day 28 in Systemic Levels of C-Reactive Protein (CRP)</measure>
    <time_frame>From baseline to Day 28</time_frame>
    <description>Difference is calculated as the geometric mean change in CRP from baseline to Day 28 of each treatment group (JNJ-41443532 250 mg, JNJ-41443532 1000 mg, and placebo). The statistical analyses shows the treatment differences (ie, each study medication group minus placebo) in the geometric mean change. CRP was not measured for pioglitazone group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Day 29 in Body Weight</measure>
    <time_frame>From baseline to Day 29</time_frame>
    <description>Difference is calculated as the change in body weight in Least Square Mean (LSM) from baseline to Day 29 of each treatment group (pioglitazone, JNJ-41443532 250 mg, JNJ-41443532 1000 mg, and placebo). The statistical analyses shows the treatment differences (ie, each study medication group minus placebo) in the LSM change.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">89</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>JNJ-41443532 250 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive JNJ-41443532 250 mg in morning and evening for 28 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>JNJ-41443532 1000 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive JNJ-41443532 1000 mg (4 X 250 mg) in morning and evening for 28 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pioglitazone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants will receive pioglitazone 30 mg in morning for 28 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will receive matching placebo for JNJ-41443532 and pioglitazone for 28 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>JNJ-41443532</intervention_name>
    <description>Participants will receive JNJ-41443532 tablet(s) orally in JNJ-41443532 250 mg arm (1 X 250 mg) and JNJ-41443532 1000 mg arm (4 X 250 mg) in morning and evening, for 28 days.</description>
    <arm_group_label>JNJ-41443532 250 mg</arm_group_label>
    <arm_group_label>JNJ-41443532 1000 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pioglitazone 30 mg</intervention_name>
    <description>Participants will receive tablet pioglitazone 30 mg orally in morning for 28 days.</description>
    <arm_group_label>Pioglitazone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Participants will receive matching placebo tablets of JNJ-41443532 and/or matching placebo tablets of pioglitazone orally as per the assigned arms.</description>
    <arm_group_label>JNJ-41443532 250 mg</arm_group_label>
    <arm_group_label>JNJ-41443532 1000 mg</arm_group_label>
    <arm_group_label>Pioglitazone</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosed Type 2 Diabetes Mellitus (T2DM) for at least 3 months prior screening

          -  On a stable treatment regimen for at least 2 months prior screening

          -  Medically stable on the basis of physical examination, medical history, and clinical
             laboratory tests performed at screening and 2 days before administration of the study
             medication

          -  Fasting plasma glucose (FPG) concentrations between 140 mg/dL and 270 mg/dL on 2 days
             before administration of the study medication

          -  Agrees to protocol-defined use of effective contraception

        Exclusion Criteria:

          -  History of other types of diabetes and complications or secondary forms of diabetes

          -  History of eating disorder or recent significant changes in body weight (ie, more or
             equal to 5 percent over 3 months prior to screening) due to dieting or nutritional
             treatments

          -  Taking antihyperglycemic agents (insulin, exenatide, and liraglutide) within 6 months
             or thiazolidinedione within 3 months of 2 days before administration of the study
             medication

          -  Clinically significant abnormal electrocardiogram

          -  History of, or currently active, significant illness or medical disorders, retinal
             disease, tuberculosis

          -  Clinically important serious infection, positive for serology at screening (hepatitis
             B surface antigen, hepatitis C antibodies or human immunodeficiency virus antibodies)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Johnson &amp; Johnson Pharmaceutical Research &amp; Development, L.L. C. Clinical Trial</last_name>
    <role>Study Director</role>
    <affiliation>Johnson &amp; Johnson Pharmaceutical Research &amp; Development, L.L.C.</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>October 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 22, 2010</study_first_submitted>
  <study_first_submitted_qc>October 28, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 29, 2010</study_first_posted>
  <results_first_submitted>March 18, 2013</results_first_submitted>
  <results_first_submitted_qc>October 17, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 11, 2013</results_first_posted>
  <disposition_first_submitted>June 8, 2012</disposition_first_submitted>
  <disposition_first_submitted_qc>June 8, 2012</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">June 11, 2012</disposition_first_posted>
  <last_update_submitted>October 17, 2013</last_update_submitted>
  <last_update_submitted_qc>October 17, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 11, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Diabetes Mellitus, Type 2</keyword>
  <keyword>Diabetes Mellitus</keyword>
  <keyword>Hyperglycemia</keyword>
  <keyword>JNJ-41443532</keyword>
  <keyword>Pioglitazone</keyword>
  <keyword>Placebo</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pioglitazone</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>89 participants were enrolled at 7 study sites in United States.</recruitment_details>
      <pre_assignment_details>89 participants were randomly assigned to 4 treatment groups (Placebo: 22; Pioglitazone 30 mg: 22; JNJ41443532 250 mg: 23, and JNJ41443532 1000 mg: 22) and all participants received at least one dose of the study medication.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>Participants received placebo tablets orally, twice a day for 29 days.</description>
        </group>
        <group group_id="P2">
          <title>Pioglitazone 30 mg</title>
          <description>Participants received pioglitazone 30 mg tablet orally, once a day for 29 days.</description>
        </group>
        <group group_id="P3">
          <title>JNJ41443532 250 mg</title>
          <description>Participants received JNJ-41443532 250 mg tablet orally, twice a day for 29 days.</description>
        </group>
        <group group_id="P4">
          <title>JNJ41443532 1000 mg</title>
          <description>Participants received JNJ-41443532 1000 mg (4 X 250 mg tablet) orally, twice a day for 29 days.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
                <participants group_id="P2" count="22"/>
                <participants group_id="P3" count="23"/>
                <participants group_id="P4" count="22"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
                <participants group_id="P2" count="20"/>
                <participants group_id="P3" count="21"/>
                <participants group_id="P4" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Fasting glucose more than 270 mg/dL</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>Participants received placebo tablets orally, twice a day for 29 days.</description>
        </group>
        <group group_id="B2">
          <title>Pioglitazone 30 mg</title>
          <description>Participants received pioglitazone 30 mg tablet orally, once a day for 29 days.</description>
        </group>
        <group group_id="B3">
          <title>JNJ41443532 250 mg</title>
          <description>Participants received JNJ-41443532 250 mg tablet orally, twice a day for 29 days.</description>
        </group>
        <group group_id="B4">
          <title>JNJ41443532 1000 mg</title>
          <description>Participants received JNJ-41443532 1000 mg (4 X 250 mg tablet) orally, twice a day for 29 days.</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="22"/>
            <count group_id="B2" value="22"/>
            <count group_id="B3" value="23"/>
            <count group_id="B4" value="22"/>
            <count group_id="B5" value="89"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="52.7" spread="8.93"/>
                    <measurement group_id="B2" value="54.5" spread="8.93"/>
                    <measurement group_id="B3" value="51.7" spread="7.06"/>
                    <measurement group_id="B4" value="57.1" spread="6.03"/>
                    <measurement group_id="B5" value="54" spread="7.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="11"/>
                    <measurement group_id="B5" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="16"/>
                    <measurement group_id="B4" value="11"/>
                    <measurement group_id="B5" value="55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline (Day -1) to Day 28 in Twenty-Four-Hour Weighted Average Glucose (24-Hour WAG)</title>
        <description>Difference is calculated as the change in 24-hour WAG in Least Square Mean (LSM) from baseline to Day 28 of each treatment group (pioglitazone, JNJ-41443532 250 mg, JNJ-41443532 1000 mg, and placebo). The statistical analyses shows the treatment differences (ie, each study medication group minus placebo) in the LSM change. 24-hour WAG is defined as the area under the plasma glucose concentration time curve over 0 to 24 hours, divided by 24.</description>
        <time_frame>From baseline (Day -1) to Day 28</time_frame>
        <population>Analyses included all participants who received at least 1 dose of JNJ-41443532 or placebo and had at least 1 pharmacodynamic assessment posttreatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Pioglitazone 30 mg</title>
            <description>Participants received pioglitazone 30 mg tablet orally, once a day for 29 days.</description>
          </group>
          <group group_id="O2">
            <title>JNJ41443532 250 mg</title>
            <description>Participants received JNJ-41443532 250 mg tablet orally, twice a day for 29 days.</description>
          </group>
          <group group_id="O3">
            <title>JNJ41443532 1000 mg</title>
            <description>Participants received JNJ-41443532 1000 mg (4 X 250 mg tablet) orally, twice a day for 29 days.</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Participants received placebo orally, twice a day for 29 days</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline (Day -1) to Day 28 in Twenty-Four-Hour Weighted Average Glucose (24-Hour WAG)</title>
          <description>Difference is calculated as the change in 24-hour WAG in Least Square Mean (LSM) from baseline to Day 28 of each treatment group (pioglitazone, JNJ-41443532 250 mg, JNJ-41443532 1000 mg, and placebo). The statistical analyses shows the treatment differences (ie, each study medication group minus placebo) in the LSM change. 24-hour WAG is defined as the area under the plasma glucose concentration time curve over 0 to 24 hours, divided by 24.</description>
          <population>Analyses included all participants who received at least 1 dose of JNJ-41443532 or placebo and had at least 1 pharmacodynamic assessment posttreatment.</population>
          <units>mg/dL</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="21"/>
                <count group_id="O3" value="20"/>
                <count group_id="O4" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-18.88" spread="7.74" lower_limit="-46.792" upper_limit="-8.008"/>
                    <measurement group_id="O2" value="-11.95" spread="7.33" lower_limit="-39.801" upper_limit="-1.142"/>
                    <measurement group_id="O3" value="-4.72" spread="7.56" lower_limit="-32.635" upper_limit="6.151"/>
                    <measurement group_id="O4" value="8.52" spread="7.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.006</p_value>
            <method>ANCOVA</method>
            <param_type>Difference in LSM</param_type>
            <param_value>-27.40</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-46.792</ci_lower_limit>
            <ci_upper_limit>-8.008</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.038</p_value>
            <method>ANCOVA</method>
            <param_type>Difference in LSM</param_type>
            <param_value>-20.47</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-39.801</ci_lower_limit>
            <ci_upper_limit>-1.142</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.178</p_value>
            <method>ANCOVA</method>
            <param_type>Difference in LSM</param_type>
            <param_value>-13.24</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-32.635</ci_lower_limit>
            <ci_upper_limit>6.151</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Day 28 in Fasting Plasma Glucose (FPG)</title>
        <description>Difference is calculated as the change in FPG in Least Square Mean (LSM) from baseline to Day 28 of each treatment group (pioglitazone, JNJ-41443532 250 mg, JNJ-41443532 1000 mg, and placebo). The statistical analyses shows the treatment differences (ie, each study medication group minus placebo) in the LSM change.</description>
        <time_frame>From baseline to Day 28</time_frame>
        <population>Analyses included all participants who received at least 1 dose of JNJ-41443532 or placebo and had at least 1 pharmacodynamic assessment posttreatment. Two participants (1 in JNJ-41443532 250-mg group and 1 in Pioglitazone group) were excluded from the analysis because a blood sample for FPG was not collected on Day 28.</population>
        <group_list>
          <group group_id="O1">
            <title>Pioglitazone 30 mg</title>
            <description>Participants received pioglitazone 30 mg tablet orally, once a day for 29 days.</description>
          </group>
          <group group_id="O2">
            <title>JNJ41443532 250 mg</title>
            <description>Participants received JNJ-41443532 250 mg tablet orally, twice a day for 29 days.</description>
          </group>
          <group group_id="O3">
            <title>JNJ41443532 1000 mg</title>
            <description>Participants received JNJ-41443532 1000 mg (4 X 250 mg tablet) orally, twice a day for 29 days.</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Participants received placebo orally, twice a day for 29 days</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Day 28 in Fasting Plasma Glucose (FPG)</title>
          <description>Difference is calculated as the change in FPG in Least Square Mean (LSM) from baseline to Day 28 of each treatment group (pioglitazone, JNJ-41443532 250 mg, JNJ-41443532 1000 mg, and placebo). The statistical analyses shows the treatment differences (ie, each study medication group minus placebo) in the LSM change.</description>
          <population>Analyses included all participants who received at least 1 dose of JNJ-41443532 or placebo and had at least 1 pharmacodynamic assessment posttreatment. Two participants (1 in JNJ-41443532 250-mg group and 1 in Pioglitazone group) were excluded from the analysis because a blood sample for FPG was not collected on Day 28.</population>
          <units>mg/dL</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="20"/>
                <count group_id="O4" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-14.57" spread="7.93" lower_limit="-47.606" upper_limit="-8.957"/>
                    <measurement group_id="O2" value="-8.26" spread="7.47" lower_limit="-41.154" upper_limit="-2.786"/>
                    <measurement group_id="O3" value="-4.00" spread="7.29" lower_limit="-36.860" upper_limit="1.431"/>
                    <measurement group_id="O4" value="13.71" spread="7.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.005</p_value>
            <method>ANCOVA</method>
            <param_type>Difference in LSM</param_type>
            <param_value>-28.28</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-47.606</ci_lower_limit>
            <ci_upper_limit>-8.957</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.025</p_value>
            <method>ANCOVA</method>
            <param_type>Difference in LSM</param_type>
            <param_value>-21.97</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-41.154</ci_lower_limit>
            <ci_upper_limit>-2.786</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.069</p_value>
            <method>ANCOVA</method>
            <param_type>Difference in LSM</param_type>
            <param_value>-17.71</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-36.860</ci_lower_limit>
            <ci_upper_limit>1.431</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Day 28 in Insulin Secretion</title>
        <description>Difference is calculated as the change in insulin secretion in Least Square Mean (LSM) from baseline to Day 28 of each treatment group (pioglitazone, JNJ-41443532 250 mg, JNJ-41443532 1000 mg, and placebo). The statistical analyses shows the treatment differences (ie, each study medication group minus placebo) in the LSM change. Insulin secretion is measured by the absolute change in Homeostasis Model Assessment of steady state islet beta cell (HOMA-%B). HOMA-%B calculated as: (360 multiplied by Insulin [pmol/L]) divided by ([Glucose {mg/dL} minus 63] multiplied by 6.945). Higher value is better (signifies improvement relative to baseline).</description>
        <time_frame>From baseline to Day 28</time_frame>
        <population>Analyses included all participants who received at least 1 dose of JNJ-41443532 or placebo and had at least 1 pharmacodynamic assessment posttreatment. Two participants (1 in JNJ-41443532 250-mg group and 1 in Pioglitazone group) were excluded from the analysis because a blood sample for HOMA-%B was not collected on Day 28.</population>
        <group_list>
          <group group_id="O1">
            <title>Pioglitazone 30 mg</title>
            <description>Participants received pioglitazone 30 mg tablet orally, once a day for 29 days.</description>
          </group>
          <group group_id="O2">
            <title>JNJ41443532 250 mg</title>
            <description>Participants received JNJ-41443532 250 mg tablet orally, twice a day for 29 days.</description>
          </group>
          <group group_id="O3">
            <title>JNJ41443532 1000 mg</title>
            <description>Participants received JNJ-41443532 1000 mg (4 X 250 mg tablet) orally, twice a day for 29 days.</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Participants received placebo orally, twice a day for 29 days</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Day 28 in Insulin Secretion</title>
          <description>Difference is calculated as the change in insulin secretion in Least Square Mean (LSM) from baseline to Day 28 of each treatment group (pioglitazone, JNJ-41443532 250 mg, JNJ-41443532 1000 mg, and placebo). The statistical analyses shows the treatment differences (ie, each study medication group minus placebo) in the LSM change. Insulin secretion is measured by the absolute change in Homeostasis Model Assessment of steady state islet beta cell (HOMA-%B). HOMA-%B calculated as: (360 multiplied by Insulin [pmol/L]) divided by ([Glucose {mg/dL} minus 63] multiplied by 6.945). Higher value is better (signifies improvement relative to baseline).</description>
          <population>Analyses included all participants who received at least 1 dose of JNJ-41443532 or placebo and had at least 1 pharmacodynamic assessment posttreatment. Two participants (1 in JNJ-41443532 250-mg group and 1 in Pioglitazone group) were excluded from the analysis because a blood sample for HOMA-%B was not collected on Day 28.</population>
          <units>HOMA-B score</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="20"/>
                <count group_id="O4" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.00" spread="4.644" lower_limit="-15.852" upper_limit="26.334"/>
                    <measurement group_id="O2" value="6.94" spread="4.415" lower_limit="3.146" upper_limit="45.370"/>
                    <measurement group_id="O3" value="-0.89" spread="4.301" lower_limit="-8.022" upper_limit="34.107"/>
                    <measurement group_id="O4" value="-6.76" spread="4.255"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.628</p_value>
            <method>ANCOVA</method>
            <param_type>Difference in LSM</param_type>
            <param_value>2.76</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-8.542</ci_lower_limit>
            <ci_upper_limit>14.054</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.018</p_value>
            <method>ANCOVA</method>
            <param_type>Difference in LSM</param_type>
            <param_value>13.70</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.392</ci_lower_limit>
            <ci_upper_limit>25.008</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.303</p_value>
            <method>ANCOVA</method>
            <param_type>Difference in LSM</param_type>
            <param_value>5.87</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.417</ci_lower_limit>
            <ci_upper_limit>17.148</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Day 28 in Insulin Resistance</title>
        <description>Difference is calculated as the change in insulin resistance in Least Square Mean (LSM) from baseline to Day 28 of each treatment group (pioglitazone, JNJ-41443532 250 mg, JNJ-41443532 1000 mg, and placebo). The statistical analyses shows the treatment differences (ie, each study medication group minus placebo) in the LSM change. Insuline sensitivity is measured by absolute change in Homeostasis Model Assessment of insulin resistance (HOMA-IR). Insulin sensitivity is HOMA-%S and HOMA-IR is the reciprocal of HOMA-%S. HOMA-IR calculated as: (Glucose [mg/dL]) multiplied by Insulin [pmol/L]) divided by (405 multiplied by 6.945). Lower value is better (signifies improvement relative to baseline).</description>
        <time_frame>From baseline to Day 28</time_frame>
        <population>Analyses included all participants who received at least 1 dose of JNJ-41443532 or placebo and had at least 1 pharmacodynamic assessment posttreatment. Two participants (1 in JNJ-41443532 250-mg group and 1 in Pioglitazone group) were excluded from the analysis because a blood sample for HOMA-IR was not collected on Day 28.</population>
        <group_list>
          <group group_id="O1">
            <title>Pioglitazone 30 mg</title>
            <description>Participants received pioglitazone 30 mg tablet orally, once a day for 29 days.</description>
          </group>
          <group group_id="O2">
            <title>JNJ41443532 250 mg</title>
            <description>Participants received JNJ-41443532 250 mg tablet orally, twice a day for 29 days.</description>
          </group>
          <group group_id="O3">
            <title>JNJ41443532 1000 mg</title>
            <description>Participants received JNJ-41443532 1000 mg (4 X 250 mg tablet) orally, twice a day for 29 days.</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Participants received placebo orally, twice a day for 29 days</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Day 28 in Insulin Resistance</title>
          <description>Difference is calculated as the change in insulin resistance in Least Square Mean (LSM) from baseline to Day 28 of each treatment group (pioglitazone, JNJ-41443532 250 mg, JNJ-41443532 1000 mg, and placebo). The statistical analyses shows the treatment differences (ie, each study medication group minus placebo) in the LSM change. Insuline sensitivity is measured by absolute change in Homeostasis Model Assessment of insulin resistance (HOMA-IR). Insulin sensitivity is HOMA-%S and HOMA-IR is the reciprocal of HOMA-%S. HOMA-IR calculated as: (Glucose [mg/dL]) multiplied by Insulin [pmol/L]) divided by (405 multiplied by 6.945). Lower value is better (signifies improvement relative to baseline).</description>
          <population>Analyses included all participants who received at least 1 dose of JNJ-41443532 or placebo and had at least 1 pharmacodynamic assessment posttreatment. Two participants (1 in JNJ-41443532 250-mg group and 1 in Pioglitazone group) were excluded from the analysis because a blood sample for HOMA-IR was not collected on Day 28.</population>
          <units>HOMA-IR score</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="20"/>
                <count group_id="O4" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.52" spread="0.739" lower_limit="-48.370" upper_limit="-7.180"/>
                    <measurement group_id="O2" value="0.07" spread="0.689" lower_limit="-24.534" upper_limit="16.542"/>
                    <measurement group_id="O3" value="-0.35" spread="0.675" lower_limit="-30.592" upper_limit="10.615"/>
                    <measurement group_id="O4" value="0.33" spread="0.666"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.041</p_value>
            <method>ANCOVA</method>
            <param_type>Difference in LSM</param_type>
            <param_value>-1.86</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.634</ci_lower_limit>
            <ci_upper_limit>-0.082</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.769</p_value>
            <method>ANCOVA</method>
            <param_type>Difference in LSM</param_type>
            <param_value>-0.26</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.033</ci_lower_limit>
            <ci_upper_limit>1.509</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.444</p_value>
            <method>ANCOVA</method>
            <param_type>Difference in LSM</param_type>
            <param_value>-0.69</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.463</ci_lower_limit>
            <ci_upper_limit>1.091</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Day 28 in Systemic Levels of Interleukin 6 (IL-6)</title>
        <description>Difference is calculated as the geometric mean change in IL-6 from baseline to Day 28 of each treatment group (JNJ-41443532 250 mg, JNJ-41443532 1000 mg, and placebo). The statistical analyses shows the treatment differences (ie, each study medication group minus placebo) in the geometric mean change. IL-6 is a systemic inflammatory markers and is an independent predictors of insulin resistance and progression to type 2 diabetes mellitus. IL-6 was not measured for pioglitazone guoup. The unit of IL-6 is picograms per milliliter (pg/mL).</description>
        <time_frame>From baseline to Day 28</time_frame>
        <population>Analyses included all participants who received at least 1 dose of JNJ-41443532 or placebo and had at least 1 pharmacodynamic assessment posttreatment.</population>
        <group_list>
          <group group_id="O1">
            <title>JNJ41443532 250 mg</title>
            <description>Participants received JNJ-41443532 250 mg tablet orally, twice a day for 29 days.</description>
          </group>
          <group group_id="O2">
            <title>JNJ41443532 1000 mg</title>
            <description>Participants received JNJ-41443532 1000 mg (4 X 250 mg tablet) orally, twice a day for 29 days.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Participants received placebo orally, twice a day for 29 days</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Day 28 in Systemic Levels of Interleukin 6 (IL-6)</title>
          <description>Difference is calculated as the geometric mean change in IL-6 from baseline to Day 28 of each treatment group (JNJ-41443532 250 mg, JNJ-41443532 1000 mg, and placebo). The statistical analyses shows the treatment differences (ie, each study medication group minus placebo) in the geometric mean change. IL-6 is a systemic inflammatory markers and is an independent predictors of insulin resistance and progression to type 2 diabetes mellitus. IL-6 was not measured for pioglitazone guoup. The unit of IL-6 is picograms per milliliter (pg/mL).</description>
          <population>Analyses included all participants who received at least 1 dose of JNJ-41443532 or placebo and had at least 1 pharmacodynamic assessment posttreatment.</population>
          <units>pg/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.86" spread="0.85" lower_limit="71.031" upper_limit="127.324"/>
                    <measurement group_id="O2" value="0.81" spread="0.34" lower_limit="66.567" upper_limit="121.403"/>
                    <measurement group_id="O3" value="0.91" spread="0.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.774</p_value>
            <method>ANCOVA</method>
            <param_type>GMR mulitplied by 100 percent</param_type>
            <param_value>95.10</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>71.031</ci_lower_limit>
            <ci_upper_limit>127.324</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.555</p_value>
            <method>ANCOVA</method>
            <param_type>GMR multiplied by 100 percent</param_type>
            <param_value>89.90</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>66.567</ci_lower_limit>
            <ci_upper_limit>121.403</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Day 28 in Systemic Levels of Interleukin 18 (IL-18)</title>
        <description>Difference is calculated as the geometric mean change in IL-18 from baseline to Day 28 of each treatment group (JNJ-41443532 250 mg, JNJ-41443532 1000 mg, and placebo). The statistical analyses shows the treatment differences (ie, each study medication group minus placebo) in the geometric mean change. IL-18 was not measured for pioglitazone group. The unit of IL-18 is picograms per milliliter (pg/mL)</description>
        <time_frame>From baseline to Day 28</time_frame>
        <population>Analyses included all participants who received at least 1 dose of JNJ-41443532 or placebo and had at least 1 pharmacodynamic assessment posttreatment.</population>
        <group_list>
          <group group_id="O1">
            <title>JNJ41443532 250 mg</title>
            <description>Participants received JNJ-41443532 250 mg tablet orally, twice a day for 29 days.</description>
          </group>
          <group group_id="O2">
            <title>JNJ41443532 1000 mg</title>
            <description>Participants received JNJ-41443532 1000 mg (4 X 250 mg tablet) orally, twice a day for 29 days.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Participants received placebo orally, twice a day for 29 days</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Day 28 in Systemic Levels of Interleukin 18 (IL-18)</title>
          <description>Difference is calculated as the geometric mean change in IL-18 from baseline to Day 28 of each treatment group (JNJ-41443532 250 mg, JNJ-41443532 1000 mg, and placebo). The statistical analyses shows the treatment differences (ie, each study medication group minus placebo) in the geometric mean change. IL-18 was not measured for pioglitazone group. The unit of IL-18 is picograms per milliliter (pg/mL)</description>
          <population>Analyses included all participants who received at least 1 dose of JNJ-41443532 or placebo and had at least 1 pharmacodynamic assessment posttreatment.</population>
          <units>pg/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.02" spread="0.16" lower_limit="93.217" upper_limit="107.647"/>
                    <measurement group_id="O2" value="1.03" spread="0.12" lower_limit="94.179" upper_limit="108.700"/>
                    <measurement group_id="O3" value="1.02" spread="0.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.968</p_value>
            <method>ANCOVA</method>
            <param_type>GMR multiplied by 100 percent</param_type>
            <param_value>100.17</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>93.217</ci_lower_limit>
            <ci_upper_limit>107.647</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.785</p_value>
            <method>ANCOVA</method>
            <param_type>GMR multiplied by 100 percent</param_type>
            <param_value>101.18</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>94.179</ci_lower_limit>
            <ci_upper_limit>108.700</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Day 28 in Systemic Levels of C-Reactive Protein (CRP)</title>
        <description>Difference is calculated as the geometric mean change in CRP from baseline to Day 28 of each treatment group (JNJ-41443532 250 mg, JNJ-41443532 1000 mg, and placebo). The statistical analyses shows the treatment differences (ie, each study medication group minus placebo) in the geometric mean change. CRP was not measured for pioglitazone group.</description>
        <time_frame>From baseline to Day 28</time_frame>
        <population>Analyses included all participants who received at least 1 dose of JNJ-41443532 or placebo and had at least 1 pharmacodynamic assessment posttreatment.</population>
        <group_list>
          <group group_id="O1">
            <title>JNJ41443532 250 mg</title>
            <description>Participants received JNJ-41443532 250 mg tablet orally, twice a day for 29 days.</description>
          </group>
          <group group_id="O2">
            <title>JNJ41443532 1000 mg</title>
            <description>Participants received JNJ-41443532 1000 mg (4 X 250 mg tablet) orally, twice a day for 29 days.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Participants received placebo orally, twice a day for 29 days</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Day 28 in Systemic Levels of C-Reactive Protein (CRP)</title>
          <description>Difference is calculated as the geometric mean change in CRP from baseline to Day 28 of each treatment group (JNJ-41443532 250 mg, JNJ-41443532 1000 mg, and placebo). The statistical analyses shows the treatment differences (ie, each study medication group minus placebo) in the geometric mean change. CRP was not measured for pioglitazone group.</description>
          <population>Analyses included all participants who received at least 1 dose of JNJ-41443532 or placebo and had at least 1 pharmacodynamic assessment posttreatment.</population>
          <units>mg/dL</units>
          <param>Geometric Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.12" spread="0.56" lower_limit="100.275" upper_limit="177.115"/>
                    <measurement group_id="O2" value="0.86" spread="0.30" lower_limit="76.260" upper_limit="135.942"/>
                    <measurement group_id="O3" value="0.84" spread="0.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.097</p_value>
            <method>ANCOVA</method>
            <param_type>GMR multiplied by 100 percent</param_type>
            <param_value>133.27</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>100.275</ci_lower_limit>
            <ci_upper_limit>177.115</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.917</p_value>
            <method>ANCOVA</method>
            <param_type>GMR mulitplied by 100 percent</param_type>
            <param_value>101.82</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>76.260</ci_lower_limit>
            <ci_upper_limit>135.942</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Day 29 in Body Weight</title>
        <description>Difference is calculated as the change in body weight in Least Square Mean (LSM) from baseline to Day 29 of each treatment group (pioglitazone, JNJ-41443532 250 mg, JNJ-41443532 1000 mg, and placebo). The statistical analyses shows the treatment differences (ie, each study medication group minus placebo) in the LSM change.</description>
        <time_frame>From baseline to Day 29</time_frame>
        <population>Analyses included all participants who received at least 1 dose of JNJ-41443532 or placebo and had at least 1 pharmacodynamic assessment posttreatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Pioglitazone 30 mg</title>
            <description>Participants received pioglitazone 30 mg tablet orally, once a day for 29 days.</description>
          </group>
          <group group_id="O2">
            <title>JNJ41443532 250 mg</title>
            <description>Participants received JNJ-41443532 250 mg tablet orally, twice a day for 29 days.</description>
          </group>
          <group group_id="O3">
            <title>JNJ41443532 1000 mg</title>
            <description>Participants received JNJ-41443532 1000 mg (4 X 250 mg tablet) orally, twice a day for 29 days.</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Participants received placebo orally, twice a day for 29 days</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Day 29 in Body Weight</title>
          <description>Difference is calculated as the change in body weight in Least Square Mean (LSM) from baseline to Day 29 of each treatment group (pioglitazone, JNJ-41443532 250 mg, JNJ-41443532 1000 mg, and placebo). The statistical analyses shows the treatment differences (ie, each study medication group minus placebo) in the LSM change.</description>
          <population>Analyses included all participants who received at least 1 dose of JNJ-41443532 or placebo and had at least 1 pharmacodynamic assessment posttreatment.</population>
          <units>Kilograms</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="21"/>
                <count group_id="O3" value="20"/>
                <count group_id="O4" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.75" spread="0.35" lower_limit="-0.408" upper_limit="1.323"/>
                    <measurement group_id="O2" value="-1.18" spread="0.34" lower_limit="-0.838" upper_limit="0.904"/>
                    <measurement group_id="O3" value="-0.19" spread="0.34" lower_limit="0.150" upper_limit="1.892"/>
                    <measurement group_id="O4" value="-1.21" spread="0.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.295</p_value>
            <method>ANCOVA</method>
            <param_type>Difference in LSM</param_type>
            <param_value>0.46</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.408</ci_lower_limit>
            <ci_upper_limit>1.323</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.941</p_value>
            <method>ANCOVA</method>
            <param_type>Difference in LSM</param_type>
            <param_value>0.03</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.838</ci_lower_limit>
            <ci_upper_limit>0.904</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.022</p_value>
            <method>ANCOVA</method>
            <param_type>Difference in LSM</param_type>
            <param_value>1.02</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.150</ci_lower_limit>
            <ci_upper_limit>1.892</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>12 weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>Participants received placebo tablets orally, twice a day for 29 days.</description>
        </group>
        <group group_id="E2">
          <title>Pioglitazone 30 mg</title>
          <description>Participants received pioglitazone 30 mg tablet orally, once a day for 29 days.</description>
        </group>
        <group group_id="E3">
          <title>JNJ41443532 250 mg</title>
          <description>Participants received JNJ-41443532 250 mg tablet orally, twice a day for 29 days.</description>
        </group>
        <group group_id="E4">
          <title>JNJ41443532 1000 mg</title>
          <description>Participants received JNJ-41443532 1000 mg (4 X 250 mg tablet) orally, twice a day for 29 days.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 14.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebrovascular Accident</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 14.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="22"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="22"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Vision Blurred</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="22"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="22"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Dry Mouth</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="22"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="22"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Upper Respiratory Tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Muscle Strain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="22"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="22"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="22"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="22"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="22"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Oropharyngeal Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Director, Translational Medicine</name_or_title>
      <organization>Janssen R&amp;D US</organization>
      <phone>1 908 927-7881</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

